Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Simcere Reports Fourth Quarter Sales Growth; Preparing For Health Care Reforms

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China-based Simcere Pharmaceutical Group reported a spike in the sales of its two main products, anti-cancer drug Endu and injectable edaravone Bicun in its fourth quarter 2007 financial results.

You may also be interested in...



CFO of China’s Simcere Sees Year of Acquisitions For 2008 - PharmAsia News Spotlight

BEIJING - One of China's leading drug makers, Simcere Pharmaceutical Group, is set to speed up its expansion through a series of acquisitions throughout 2008

CFO of China’s Simcere Sees Year of Acquisitions For 2008 - PharmAsia News Spotlight

BEIJING - One of China's leading drug makers, Simcere Pharmaceutical Group, is set to speed up its expansion through a series of acquisitions throughout 2008

Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda

Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel